Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | IAPP | P10997 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238983 | 0.85 | ALDH1A1 (0.43) | HSPA5TAAR1TSHRHIF1ACA2 | |
| SCHEMBL8918996 | 0.85 | TDP1 (0.42) | TAAR1TSHRCA2TDP1ALDH1A1 | |
| SCHEMBL11094348 | 0.82 | BID (0.56) | TSHRTDP1MMP2ALOX15HSD17B10 | |
| SCHEMBL1951548 | 0.79 | IAPP (0.57) | HSPA5TAAR1IAPPCYP2D6TSHR | |
| SCHEMBL30046415 | 0.79 | IAPP (0.57) | HSPA5TAAR1IAPPCYP2D6TSHR | |
| SCHEMBL43837 | 0.78 | TAAR1 (0.62) | HSPA5TAAR1CYP2D6TSHRHIF1A | |
| SCHEMBL29646276 | 0.78 | TAAR1 (0.62) | HSPA5TAAR1CYP2D6TSHRHIF1A | |
| SCHEMBL16346142 | 0.78 | BID (0.36) | HIF1AHTR2AGABRA1GABRB2 | |
| SCHEMBL5596024 | 0.77 | TDP1 (0.36) | TSHRCA2TDP1ALDH1A1GABRA1 | |
| SCHEMBL10624720 | 0.77 | TAAR1 (0.45) | HSPA5TAAR1IAPPCYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320188-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12304896-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240336584-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2024-10-10 | — | — | US | disclosed |
| US-12049457-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230382883-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382883-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382883-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | VANDA PHARMACEUTICALS INC. | 2023-11-30 | — | — | US | disclosed |
| US-11760740-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760740-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760740-B2 | Highly purified pharmaceutical grade tasimelteon | VANDA PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20120083526-A1 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2012-04-05 | — | — | US | disclosed |
| US-20120083526-A1 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2012-04-05 | — | — | US | disclosed |
| EP-2417117-A2 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK Pharmaceuticals d.d. (SI) | 2012-02-15 | — | — | EP | disclosed |
| EP-2243775-A1 | Synthesis of 1-(2,3-Dihydrobenzofuran-4-YL)ethanone as intermediate in the preparation of ramelteon | LEK Pharmaceuticals d.d. (SI) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010115897-A2 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010115897-A2 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | LEK PHARMACEUTICALS D.D. (SI) | 2010-10-14 | — | — | WO | disclosed |
| EP-0901483-B1 | BENZOFURANS AND BENZOPYRANS AS CHRONOBIOLOGICAL AGENTS | GLAXO GROUP LTD (GB) | 2003-07-09 | — | — | EP | disclosed |
| US-5981572-A | Benzofurans and benzopyrans as chronobiological agents | GLAXO WELLCOME INC. (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0901483-A2 | BENZOFURANS AND BENZOPYRANS AS CHRONOBIOLOGICAL AGENTS | GLAXO GROUP LIMITED (GB) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043272-A2 | BENZOFURANS AND BENZOPYRANS AS CHRONOBIOLOGICAL AGENTS | GLAXO GROUP LIMITED (GB) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12304896-B2 | Highly purified pharmaceutical grade tasimelteon | GMPS, TAS2R45, TAS2R10 | HSPA5 4107/4885TAAR1 1014/4885IAPP 871/4885 |
| US-20250320188-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | GMPS, TAS2R45, TAS2R10 | HSPA5 4107/4885TAAR1 1014/4885IAPP 871/4885 |
| US-20230382883-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | GMPS, TAS2R45, TAS2R10 | HSPA5 4107/4885TAAR1 1014/4885IAPP 871/4885 |
| US-11760740-B2 | Highly purified pharmaceutical grade tasimelteon | GMPS, TAS2R45, TAS2R10 | HSPA5 4107/4885TAAR1 1014/4885IAPP 871/4885 |
| US-20120083526-A1 | SYNTHESIS OF 1-(2,3-DIHYDROBENZOFURAN-4-YL)ETHANONE AS INTERMEDIATE IN THE PREPARATION OF RAMELTEON | CYP2J2, CYP2E1, CYP2B6 | HSPA5 860/4885TAAR1 3764/4885IAPP 4385/4885 |
| US-12049457-B2 | Highly purified pharmaceutical grade tasimelteon | GMPS, TAS2R45, TAS2R10 | HSPA5 4107/4885TAAR1 1014/4885IAPP 871/4885 |
| US-20240336584-A1 | HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON | GMPS, TAS2R45, TAS2R10 | HSPA5 4107/4885TAAR1 1014/4885IAPP 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.